The relationship between intestinal inflammation and behavioral changes has become one of the more compelling frontiers in gastroenterology and neuroscience research. The study under discussion adds to a growing body of literature suggesting that the gut and the brain communicate in ways that are far more consequential than previously appreciated. When the intestinal lining becomes inflamed, as it does in ulcerative colitis, signaling molecules released at the site of injury do not simply remain confined to the gut. Instead, they can enter systemic circulation and potentially influence distant organs, including the brain. This phenomenon, often described through the lens of the gut-brain axis, provides a plausible biological framework for understanding why patients with inflammatory bowel disease frequently report symptoms such as anxiety, low mood, and impaired quality of life that extend well beyond their gastrointestinal complaints.

Dexpanthenol, the alcohol analog of pantothenic acid or vitamin B5, has long been recognized for its role in wound healing and epithelial repair. It is commonly found in topical ointments and creams designed to soothe irritated skin, and it has also been used in some settings to support mucosal healing in the gastrointestinal tract. Its pharmacological profile includes antioxidant properties, modulation of inflammatory pathways, and the ability to promote cellular regeneration. These characteristics made it a reasonable candidate for investigation in the context of colitis, where the intestinal mucosa is subject to significant oxidative and inflammatory damage. What makes the present findings particularly interesting is that the benefits observed were not limited to the gut itself but extended to behavioral measures and to inflammatory markers measured in brain tissue.

The experimental model used in this research involved the intracolonic administration of dilute acetic acid, a well-established method for inducing colonic inflammation in rodents. This approach produces tissue injury that shares several features with human ulcerative colitis, including epithelial disruption, neutrophil infiltration, and elevated production of pro-inflammatory mediators. While no animal model perfectly recapitulates the human condition, the acetic acid model has proven useful for studying the acute inflammatory phase of colonic injury and for screening compounds with potential therapeutic value. The researchers paired this model with a battery of behavioral assessments that are standard in the study of anxiety-like states in laboratory rodents, providing a multidimensional picture of how colonic inflammation affects emotional behavior.

The open field test, one of the three behavioral paradigms employed, measures an animal’s willingness to explore an unfamiliar open space. Rodents naturally avoid open, brightly lit areas, and increased avoidance is interpreted as heightened anxiety. The elevated plus maze relies on a similar principle, presenting animals with a choice between enclosed, protected arms and open, exposed arms of an elevated apparatus. Anxious animals spend less time in the open arms. The light-dark box takes advantage of the same innate preference for darkened environments, quantifying the balance between natural curiosity and aversion to bright illumination. Together, these three tests provide convergent evidence about anxiety-like states, and their consistent use across the experimental groups strengthens the interpretive weight of the findings.

The measurement of inflammatory cytokines in serum, colon tissue, and hippocampal tissue represents a particularly valuable aspect of the study design. Interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta are among the most extensively studied pro-inflammatory cytokines in the context of both peripheral inflammation and central nervous system signaling. Tumor necrosis factor-alpha, for instance, is already the target of approved biologic therapies for ulcerative colitis, and its role in driving mucosal inflammation is well characterized. Interleukin-6 has been implicated in the transition from acute to chronic inflammation and has also been associated with mood disturbances in various clinical populations. Interleukin-1 beta plays a central role in the initiation and amplification of inflammatory responses and has been shown to influence neural circuits involved in stress and emotion. The finding that dexpanthenol treatment reduced levels of all three cytokines across multiple tissue compartments suggests a broad anti-inflammatory effect rather than a narrow modulation of a single pathway.

The hippocampus deserves particular attention in this context. This brain structure is not only critical for memory formation and spatial navigation but also plays a significant role in the regulation of the stress response through its connections with the hypothalamic-pituitary-adrenal axis. Chronic inflammation has been shown to affect hippocampal function in ways that can alter emotional behavior, and hippocampal inflammation has been linked to anxiety and depressive-like states in multiple experimental models. The observation that inflammatory cytokine levels were elevated in the hippocampus of colitic animals and reduced by dexpanthenol treatment provides a direct tissue-level correlate for the behavioral changes documented in the study. This kind of concordance between peripheral inflammation, central inflammation, and behavior is exactly what would be expected if the gut-brain axis were operating as a genuine biological pathway rather than as a mere correlation.

It is worth considering the broader clinical implications of these findings. Patients with ulcerative colitis commonly report anxiety, and this anxiety can persist even during periods of clinical remission when gastrointestinal symptoms are well controlled. This observation has led some investigators to propose that the behavioral consequences of intestinal inflammation may not be entirely secondary to the discomfort of active disease but may reflect lasting alterations in inflammatory signaling that affect the brain. If this is the case, then treatments that reduce both peripheral and central inflammation could offer benefits that extend beyond mucosal healing. The present study, while conducted in an animal model, provides preliminary support for this idea by demonstrating that a compound with established safety in humans can influence both colonic and hippocampal inflammation in the context of experimental colitis.

The dose of dexpanthenol used in the study, 500 milligrams per kilogram administered intraperitoneally, is relatively high compared with typical human exposures from topical or oral use. This is an important consideration when translating the findings to clinical practice. Intraperitoneal administration in rodents produces rapid and near-complete systemic absorption, whereas oral or topical routes in humans result in different pharmacokinetic profiles. Nevertheless, the choice of dose and route is common in preclinical pharmacology research, where the goal is often to establish proof of concept before optimizing delivery strategies. Future studies would need to explore whether lower doses or alternative routes of administration could achieve similar effects, and whether prolonged treatment regimens would be necessary to sustain the benefits observed.

The sample size of eight animals per group is modest but not unusual for studies of this type. Small sample sizes in animal research can limit statistical power and increase the risk of both false-positive and false-negative findings. However, the consistency of the results across multiple behavioral tests and multiple tissue compartments provides some reassurance that the observed effects are not simply artifacts of random variation. Replication in larger cohorts and in alternative models of colitis would strengthen confidence in the findings and help determine whether the effects generalize beyond the specific conditions of the acetic acid model.

The mechanism by which dexpanthenol reduces inflammation in this setting is not fully elucidated by the study, and the authors appropriately call for further mechanistic investigation. Several possibilities merit consideration. Dexpanthenol is converted in vivo to pantothenic acid, which serves as a precursor for coenzyme A, a molecule central to cellular metabolism and to the synthesis of acetylcholine. Acetylcholine itself has well-documented anti-inflammatory effects through the cholinergic anti-inflammatory pathway, a neural circuit that links the vagus nerve to immune cells in the spleen and other organs. Activation of this pathway has been shown to reduce the release of pro-inflammatory cytokines from macrophages and other immune cells. Whether dexpanthenol’s effects in this study operate through enhanced cholinergic signaling, through direct antioxidant activity, through modulation of nuclear factor-kappa B signaling, or through some combination of these mechanisms remains an open question that future research will need to address.

The oxidative stress component of colitis is another area where dexpanthenol’s pharmacological profile may be relevant. Intestinal inflammation generates substantial quantities of reactive oxygen species, which contribute to tissue damage and can also serve as signaling molecules that amplify inflammatory responses. Compounds with antioxidant properties can interrupt this cycle by neutralizing reactive oxygen species and reducing the downstream activation of inflammatory pathways. Dexpanthenol has demonstrated antioxidant effects in several experimental contexts, and this activity may contribute to its ability to reduce cytokine production in the colon and other tissues. The interplay between oxidative stress and inflammation is complex, and disentangling the relative contributions of each to the behavioral changes observed would require additional experiments specifically designed to manipulate these pathways independently.

The study’s findings also connect to a broader literature on the role of the vagus nerve in gut-brain communication. The vagus nerve serves as a major conduit for bidirectional signaling between the gastrointestinal tract and the brain, carrying sensory information from the gut to the brainstem and motor commands from the brain to the gut. Inflammatory signals in the intestine can activate vagal afferents, which in turn influence brain regions involved in emotional regulation. Conversely, vagal efferent signaling can modulate immune activity in the gut through the cholinergic anti-inflammatory pathway mentioned earlier. This bidirectional communication means that interventions targeting either end of the vagal circuit could potentially influence both gut inflammation and brain function. Whether dexpanthenol’s effects involve vagal signaling is not established by the present study, but the convergence of peripheral and central anti-inflammatory effects is consistent with mechanisms that operate through neural circuits connecting the two compartments.

From a translational perspective, the identification of a well-tolerated compound with potential benefits for both gastrointestinal inflammation and associated behavioral disturbances is noteworthy. Dexpanthenol has an established safety record in humans, with extensive use in topical preparations and some oral and parenteral applications. This safety profile reduces one of the major barriers to clinical translation, namely the concern about toxicity that often accompanies novel therapeutic candidates. However, the specific question of whether dexpanthenol can influence anxiety in patients with ulcerative colitis has not been addressed in clinical trials, and the leap from an animal model to human patients involves many uncertainties. Human ulcerative colitis is a heterogeneous condition with multiple inflammatory pathways and varying degrees of behavioral comorbidity, and the response to any given treatment may depend on factors such as disease duration, extent of colonic involvement, and concurrent medications.

The study also raises questions about the timing of intervention relative to the onset of inflammation. In the experimental design, dexpanthenol was administered after the induction of colitis, which models a treatment scenario rather than a preventive one. Whether dexpanthenol would also be effective if given before the onset of inflammation, or whether its benefits would persist with prolonged administration after the acute inflammatory phase has subsided, are questions that future research could productively explore. The chronic nature of ulcerative colitis in humans, characterized by cycles of flare and remission, means that any potential therapy would need to demonstrate sustained efficacy over time rather than simply providing short-term relief during acute episodes.

The convergence of behavioral and biochemical data in this study reflects a methodological trend in preclinical research that emphasizes the importance of measuring both functional outcomes and the biological variables that may underlie them. Rather than simply documenting that colitic animals behave differently, the researchers sought to identify specific molecular changes in relevant tissues that could account for the behavioral observations. This approach, sometimes described as mechanistic pharmacology, provides a richer picture of drug action than behavioral testing alone and generates hypotheses that can be tested in subsequent experiments. The identification of hippocampal inflammation as a correlate of anxiety-like behavior in colitic animals, and its reduction by dexpanthenol, offers a specific target for future mechanistic studies that could manipulate this pathway directly.

The broader significance of this work lies in its contribution to the growing recognition that inflammatory bowel disease is not solely a disorder of the intestine but a condition with systemic manifestations that can affect multiple organ systems. The brain, with its intricate vulnerability to inflammatory signaling, represents one of the most clinically relevant of these targets. As research continues to clarify the pathways through which gut inflammation influences brain function, and as new therapeutic strategies are developed to interrupt these pathways, patients with inflammatory bowel disease may benefit from treatments that address not only their gastrointestinal symptoms but also the emotional and cognitive disturbances that so often accompany their condition. The present study, with its demonstration that a compound with established safety can influence both colonic and hippocampal inflammation in an animal model of colitis, represents a small but meaningful step in that direction.

Future research building on these findings could take several directions. Studies using genetic or pharmacological tools to block specific inflammatory pathways could clarify which mediators are most critical for the behavioral effects of colitis. Investigations using alternative models of colitis, including models that better recapitulate the chronic relapsing nature of human disease, could determine whether the findings generalize beyond the acute inflammatory conditions of the acetic acid model. Research exploring the dose-response relationship and the optimal route of administration could inform the design of clinical trials. And studies examining the effects of dexpanthenol in combination with established therapies for ulcerative colitis could determine whether it offers additive or synergistic benefits. Each of these avenues represents an opportunity to advance understanding of the gut-brain axis in inflammatory bowel disease and to move closer to therapies that address the full spectrum of patient experience.

Subject of Research: …

Article Title: Dexpanthenol attenuates anxiety-like behaviors and inflammatory factors in a rat model of acetic acid-induced colitis

Article References: Masoumian Rad, S. R., Rahimi, K., & Givi, M. E. (2026). Dexpanthenol attenuates anxiety-like behaviors and inflammatory factors in a rat model of acetic acid-induced colitis. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01258-1

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01258-1

Keywords: colitis, anxiety, dexpanthenol, cytokines, gut-brain axis, inflammatory bowel disease, ulcerative colitis, TNF-alpha, IL-6, IL-1 beta, hippocampus, rat model